PE20130637A1 - Suministro al sistema nervioso central de agentes terapeuticos - Google Patents

Suministro al sistema nervioso central de agentes terapeuticos

Info

Publication number
PE20130637A1
PE20130637A1 PE2012002479A PE2012002479A PE20130637A1 PE 20130637 A1 PE20130637 A1 PE 20130637A1 PE 2012002479 A PE2012002479 A PE 2012002479A PE 2012002479 A PE2012002479 A PE 2012002479A PE 20130637 A1 PE20130637 A1 PE 20130637A1
Authority
PE
Peru
Prior art keywords
global
disease
hnsulfatasa
composition
cells
Prior art date
Application number
PE2012002479A
Other languages
English (en)
Inventor
Pericles Calias
Jing Pan
Jan Powell
Lawrence Charnas
Thomas Mccauley
Teresa Leah Wright
Richard Pfeifer
Zahra Shahrokh
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45352777&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PE20130637A1 publication Critical patent/PE20130637A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA ENZIMA DE REEMPLAZO PARA UNA ENZIMA LISOSOMAL CUYA ACTIVIDAD ESTA REDUCIDA TAL COMO IDURONATO-2-SULFATASA RECOMBINANTE (I2S), ARILSULFATASA A (ASA), HEPARAN N-SULFATASA (HNS), ALFA-N-ACETILGLUCOSAMINIDASA (Naglu) O B-GALACTOSIDASA (GLC) EN UNA CONCENTRACION MAYOR DE 5 MG/ML; B) UN AGENTE AMORTIGUADOR; C) UN TENSOACTIVO; Y D) UN TONIFICADOR; EN DONDE LA COMPOSICION TIENE UN PH DE 3.0 A 8.0. TAMBIEN SE REFIERE A UN METODO DE TRATAMIENTO DE UNA ENFERMEDAD DE ALMACENAMIENTO LISOSOMAL TAL COMO EL SINDROME DE HUNTERS, ENFERMEDAD DE LEUCODISTROFIA METACROMATICA (MLD), SINDROME DE SANFILIPPO TIPO A Y B, Y LA ENFERMEDAD DE LEUCODISTROFIA DE CELULAS GLOBOIDES (GLD) QUE COMPRENDE ADMINISTRAR INTRATECALMENTE DICHA COMPOSICION DE UNA ENZIMA DE REEMPLAZO PARA SER SUMINISTRADA A NEURONAS, CELULAS GLIALES, CELULAS PERIVASCULARES Y CELULAS MENINGEALES. DICHO METODO DE TRATAMIENTO ES MENOS INVASIVO
PE2012002479A 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos PE20130637A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35885710P 2010-06-25 2010-06-25
US36078610P 2010-07-01 2010-07-01
US38786210P 2010-09-29 2010-09-29
US201161435710P 2011-01-24 2011-01-24
US201161442115P 2011-02-11 2011-02-11
US201161476210P 2011-04-15 2011-04-15
US201161495268P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
PE20130637A1 true PE20130637A1 (es) 2013-06-13

Family

ID=45352777

Family Applications (8)

Application Number Title Priority Date Filing Date
PE2012002498A PE20130648A1 (es) 2010-06-25 2011-06-25 Tratamiento del sindrome de sanfilippo tipo b
PE2012002479A PE20130637A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2012002474A PE20130578A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE2017000503A PE20170938A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2017001612A PE20180130A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2012002475A PE20130579A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2018000183A PE20180801A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2012002476A PE20130589A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012002498A PE20130648A1 (es) 2010-06-25 2011-06-25 Tratamiento del sindrome de sanfilippo tipo b

Family Applications After (6)

Application Number Title Priority Date Filing Date
PE2012002474A PE20130578A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
PE2017000503A PE20170938A1 (es) 2010-06-25 2011-06-25 Suministro al sistema nervioso central de agentes terapeuticos
PE2017001612A PE20180130A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
PE2012002475A PE20130579A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2018000183A PE20180801A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
PE2012002476A PE20130589A1 (es) 2010-06-25 2011-06-25 Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a

Country Status (24)

Country Link
US (14) US9814764B2 (es)
JP (21) JP6250616B2 (es)
CN (4) CN106139133B (es)
AR (6) AR081677A1 (es)
BR (1) BR112012033214B1 (es)
CA (1) CA3171308A1 (es)
CL (7) CL2012003655A1 (es)
DK (3) DK3103469T3 (es)
ES (3) ES2895655T3 (es)
HK (2) HK1214149A1 (es)
HR (3) HRP20211660T1 (es)
HU (6) HUE052944T2 (es)
LT (3) LT3103469T (es)
MX (1) MX354776B (es)
NZ (2) NZ702803A (es)
PE (8) PE20130648A1 (es)
PL (1) PL2588130T3 (es)
PT (6) PT3103469T (es)
RS (3) RS62620B1 (es)
RU (1) RU2761342C2 (es)
SI (3) SI3626257T1 (es)
SM (1) SMT201600385B (es)
TW (8) TWI669128B (es)
UA (2) UA125743C2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5959795B2 (ja) 2006-08-18 2016-08-02 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 血液脳関門送達のための物質
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
IL291554B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
DK3103469T3 (en) 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
DK2585104T3 (da) 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger tilcns-levering af arylsulfatase a
CA2857647C (en) 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
ES2728447T3 (es) 2011-12-23 2019-10-24 Shire Human Genetic Therapies Tratamiento del déficit cognitivo del síndrome de Hunter para la administración intratecal de iduronato-2-sulfatasa
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN115120745A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经***转移
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3292206B8 (en) 2015-05-07 2022-02-09 Takeda Pharmaceutical Company Limited Glucocerebrosidase gene therapy for parkinson's disease
PE20181329A1 (es) * 2015-12-30 2018-08-20 Green Cross Corp Metodos y composiciones para el tratamiento del sindrome de hunter
US11345904B2 (en) * 2016-02-24 2022-05-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
IL305449A (en) 2016-04-15 2023-10-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
CA3076036A1 (en) 2017-09-22 2019-03-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CA3092218A1 (en) * 2018-02-28 2019-09-06 Seikagaku Corporation Package and method for producing the same
CN108534695A (zh) * 2018-05-04 2018-09-14 无锡恩特卫自动化检测设备有限公司 一种基于机器视觉***的瓶塞漏酒检测方法及装置
KR102671857B1 (ko) * 2018-05-30 2024-06-04 주식회사 녹십자 대뇌 측뇌실 투여에 의해 헌터증후군을 치료하기 위한 방법 및 조성물
WO2020004368A1 (ja) 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
JP7253771B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
JP7253770B2 (ja) * 2019-01-18 2023-04-07 株式会社大一商会 遊技機
EP4229192A1 (en) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
CN113283465B (zh) * 2021-04-02 2022-04-29 电子科技大学 一种弥散张量成像数据分析方法及装置
CN115116623A (zh) * 2022-06-28 2022-09-27 深圳市儿童医院 一种基于icd疾病编码的抗菌药物使用指标评价方法、终端

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133001A (en) * 1959-11-26 1964-05-12 Muset Pedro Puig Stabilization of enzymes
US4743265A (en) 1986-04-23 1988-05-10 Dij Catheter Corp Articulated catheter placement device
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
US5863782A (en) * 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPN674895A0 (en) 1995-11-23 1995-12-14 Women's And Children's Hospital Synthetic mammalian alpha-N-acetylglucosaminidase and genetic sequences encoding same
EP0900569B1 (en) 1997-08-22 2002-10-02 Seikagaku Corporation Therapeutic agent for herniated intervertebral disc
KR20010101131A (ko) 1998-12-07 2001-11-14 추후기재 폼페병의 치료 방법
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6368315B1 (en) 1999-06-23 2002-04-09 Durect Corporation Composite drug delivery catheter
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020099025A1 (en) * 1999-12-30 2002-07-25 Heywood James A. Treatment of neurological disorders
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
CA2445577C (en) 2001-04-30 2012-07-03 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
IL161352A0 (en) 2001-10-16 2004-09-27 Symbiontics Inc Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030181426A1 (en) 2002-02-11 2003-09-25 Eisenach James C. Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
NZ536361A (en) * 2002-04-25 2008-05-30 Shire Human Genetic Therapies Treatment of alpha-galactosidase a deficiency
EP1514106A4 (en) 2002-05-29 2007-05-09 Zystor Therapeutics Inc TARGETED THERAPEUTIC PROTEINS
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
ES2619353T3 (es) 2003-01-31 2017-06-26 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
EP1592709A2 (en) 2003-02-10 2005-11-09 TO-BBB Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1713904B1 (en) * 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
US20060029656A1 (en) 2004-02-03 2006-02-09 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
EP1720405A4 (en) 2004-02-06 2008-08-27 Biomarin Pharm Inc MANUFACTURE OF HIGHLY PHOSPHORYLATED LYSOSOMAL ENZYMES AND USES THEREOF
WO2005078077A2 (en) 2004-02-10 2005-08-25 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CN101310011A (zh) * 2004-06-15 2008-11-19 巴克斯特国际公司 固相微颗粒治疗剂的离体应用
KR20070046919A (ko) * 2004-08-11 2007-05-03 시바 스페셜티 케미칼스 홀딩 인크. 효소계 시간 온도 인디케이터
IL165334A0 (en) * 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
WO2006121199A1 (ja) * 2005-05-11 2006-11-16 Oxygenix Co., Ltd. 脂質小胞体組成物
CA2611011C (en) 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
JP2009526066A (ja) 2006-02-09 2009-07-16 ジェンザイム・コーポレーション 遅速性脳室内送達
CA2632528C (en) 2006-04-04 2022-07-12 Zymenex A/S A process for concentration of a polypeptide
CN101410408A (zh) * 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
WO2008070769A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
CA2680189A1 (en) 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
WO2009017005A1 (ja) 2007-07-27 2009-02-05 Sharp Kabushiki Kaisha 移動局装置、基地局装置、通信システム及びプログラム
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
WO2009062348A1 (fr) * 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Procédés d'inhibition d'une infection par le virus de la grippe et leurs médicaments
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
DK2279210T3 (en) 2008-05-07 2017-07-24 Biomarin Pharm Inc Lysosomal targeting peptides and uses thereof
US8436489B2 (en) 2009-06-29 2013-05-07 Lightsail Energy, Inc. Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange
JP6045492B2 (ja) 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド イズロン酸−２−スルファターゼのｃｎｓ送達のための方法および組成物
EP2588132A4 (en) 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
NZ605871A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
JP6073783B2 (ja) * 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
IL291554B2 (en) * 2010-06-25 2024-02-01 Shire Human Genetic Therapies Administering therapeutic agents to the central nervous system
DK3103469T3 (en) 2010-06-25 2021-02-22 Shire Human Genetic Therapies Indgivelse af terapeutiske midler til centralnervesystemet
DK2585104T3 (da) 2010-06-25 2019-10-14 Shire Human Genetic Therapies Fremgangsmåder og sammensætninger tilcns-levering af arylsulfatase a
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2793922B1 (en) * 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a

Also Published As

Publication number Publication date
TWI669128B (zh) 2019-08-21
JP2023099216A (ja) 2023-07-11
CL2012003657A1 (es) 2013-04-19
TW201726161A (zh) 2017-08-01
LT3103469T (lt) 2021-03-25
RS62620B1 (sr) 2021-12-31
US11065308B2 (en) 2021-07-20
AR081678A1 (es) 2012-10-10
PE20130648A1 (es) 2013-07-03
JP6250616B2 (ja) 2017-12-20
US20180071212A1 (en) 2018-03-15
PE20130578A1 (es) 2013-05-19
JP6522073B2 (ja) 2019-05-29
US20180085438A1 (en) 2018-03-29
PE20180130A1 (es) 2018-01-18
ES2896060T3 (es) 2022-02-23
AR081679A1 (es) 2012-10-10
JP7448507B2 (ja) 2024-03-12
US20140271598A1 (en) 2014-09-18
JP2023052868A (ja) 2023-04-12
US20230026836A1 (en) 2023-01-26
DK3103469T3 (en) 2021-02-22
TW202337489A (zh) 2023-10-01
CN106139133A (zh) 2016-11-23
PE20170938A1 (es) 2017-07-13
HRP20211660T1 (hr) 2022-02-04
US20230165942A1 (en) 2023-06-01
PT3103469T (pt) 2021-03-04
TWI698252B (zh) 2020-07-11
JP2021181489A (ja) 2021-11-25
CN104857504A (zh) 2015-08-26
CL2012003655A1 (es) 2013-04-19
PT2588130T (pt) 2016-11-25
HK1218719A1 (zh) 2017-03-10
US20220133862A1 (en) 2022-05-05
RU2018137304A (ru) 2019-03-21
DK3626258T3 (da) 2021-09-20
US10456454B2 (en) 2019-10-29
US20190183984A1 (en) 2019-06-20
CL2017002488A1 (es) 2017-12-15
LT3626257T (lt) 2021-12-10
US20200046810A1 (en) 2020-02-13
JP6346162B2 (ja) 2018-06-20
RU2018113327A (ru) 2019-03-01
US20200113981A1 (en) 2020-04-16
NZ702803A (en) 2017-05-26
HRP20210298T1 (hr) 2021-04-16
JP2020079297A (ja) 2020-05-28
US20130295077A1 (en) 2013-11-07
CL2020000468A1 (es) 2020-09-04
CL2016003159A1 (es) 2017-05-12
TW202112391A (zh) 2021-04-01
RU2017125281A3 (es) 2020-11-09
JP6466538B2 (ja) 2019-02-06
US20160158324A1 (en) 2016-06-09
ES2858726T3 (es) 2021-09-30
JP2019006826A (ja) 2019-01-17
AR082025A1 (es) 2012-11-07
TWI602573B (zh) 2017-10-21
RU2017125281A (ru) 2019-01-31
HUE046856T2 (hu) 2020-03-30
SI3626258T1 (sl) 2021-11-30
PT2593131T (pt) 2019-10-30
CL2012003656A1 (es) 2013-07-19
JP7359827B2 (ja) 2023-10-11
AR081681A1 (es) 2012-10-10
ES2895655T3 (es) 2022-02-22
HUE056884T2 (hu) 2022-03-28
PE20130579A1 (es) 2013-05-19
TWI790444B (zh) 2023-01-21
US11260112B2 (en) 2022-03-01
JP2016041755A (ja) 2016-03-31
PT3626257T (pt) 2021-11-12
TW201825111A (zh) 2018-07-16
CA3171308A1 (en) 2011-12-29
AR081677A1 (es) 2012-10-10
PT2585104T (pt) 2019-10-30
UA125743C2 (uk) 2022-06-01
JP2019031575A (ja) 2019-02-28
JP2017214434A (ja) 2017-12-07
TW201701899A (zh) 2017-01-16
RU2761342C2 (ru) 2021-12-07
TW201212936A (en) 2012-04-01
TWI609694B (zh) 2018-01-01
TW201815411A (zh) 2018-05-01
NZ702800A (en) 2017-03-31
HK1214149A1 (zh) 2016-07-22
JP6938456B2 (ja) 2021-09-22
MX354776B (es) 2018-03-20
JP2016040335A (ja) 2016-03-24
CL2012003654A1 (es) 2013-06-14
PE20130589A1 (es) 2013-05-19
CN105233277B (zh) 2019-01-01
SI3103469T1 (sl) 2021-04-30
LT3626258T (lt) 2021-12-10
RU2018113327A3 (es) 2021-07-21
TW201206465A (en) 2012-02-16
CN105233277A (zh) 2016-01-13
CN106139133B (zh) 2020-12-04
HUE046409T2 (hu) 2020-02-28
SMT201600385B (it) 2017-03-08
JP6285409B2 (ja) 2018-02-28
RS62520B1 (sr) 2021-11-30
SI3626257T1 (sl) 2021-12-31
US9220677B2 (en) 2015-12-29
HRP20211520T1 (hr) 2021-12-24
JP2021167340A (ja) 2021-10-21
JP2016040337A (ja) 2016-03-24
JP2022024176A (ja) 2022-02-08
JP6898909B2 (ja) 2021-07-07
JP7087175B2 (ja) 2022-06-20
HUE052944T2 (hu) 2021-05-28
RU2018137304A3 (es) 2022-02-22
US10646554B2 (en) 2020-05-12
BR112012033214B1 (pt) 2020-11-03
UA125060C2 (uk) 2022-01-05
HUE055963T2 (hu) 2022-01-28
JP2020079298A (ja) 2020-05-28
HUE031036T2 (en) 2017-06-28
US20170042977A1 (en) 2017-02-16
US20170042978A1 (en) 2017-02-16
US11471516B2 (en) 2022-10-18
JP6797876B2 (ja) 2020-12-09
BR112012033214A2 (pt) 2017-05-23
RS61683B1 (sr) 2021-05-31
PL2588130T3 (pl) 2017-09-29
DK3626257T3 (da) 2021-11-08
JP2016094451A (ja) 2016-05-26
US20200405825A1 (en) 2020-12-31
PE20180801A1 (es) 2018-05-09
AR081680A1 (es) 2012-10-10
JP2019038853A (ja) 2019-03-14
JP6522072B2 (ja) 2019-05-29
JP2020079244A (ja) 2020-05-28
US9814764B2 (en) 2017-11-14
CN105664142A (zh) 2016-06-15
MX2013000321A (es) 2013-04-03
JP2023062114A (ja) 2023-05-02
JP2018002735A (ja) 2018-01-11
JP2018002734A (ja) 2018-01-11
US11065307B2 (en) 2021-07-20
PT3626258T (pt) 2021-10-19
JP2016037504A (ja) 2016-03-22
JP2021167341A (ja) 2021-10-21

Similar Documents

Publication Publication Date Title
PE20130637A1 (es) Suministro al sistema nervioso central de agentes terapeuticos
PE20140841A1 (es) Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos
ES2650689T3 (es) Administración de agentes terapéuticos al sistema nervioso central
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
ES2531083T3 (es) Formulaciones estables de polipéptidos y usos de las mismas
Kozlovsky et al. Psychotropic drugs affect Ser9-phosphorylated GSK-3β protein levels in rodent frontal cortex
EA201100896A1 (ru) Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение
CR20190034A (es) INHIBIDORES DE GLUCOSILCERAMIDA SINTASA (Divisional 2013-0471)
PE20171798A1 (es) Formulacion que comprende n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada
BR112012033197A2 (pt) métodos e composições para liberação de cns de n-sulfatase de heparano.
BR112012014025A2 (pt) análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira e método de tratar um paciente
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
EA201270201A1 (ru) Липкий мягкий гель для обработки домашних птиц
BRPI0519209A2 (pt) compostos orgçnicos
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
AR071774A1 (es) Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso.
AR090244A1 (es) Formulacion de anticuerpo anti-selectina p
BR112013016554A2 (pt) métodos e composições úteis para promover sono nos animais
AR097613A1 (es) Dosificación de péptidos co-antagonistas gip/glp-1 para administración a humanos
WO2014115084A3 (en) Recombinant human paraoxonase 1 enzymes, method of generation and uses thereof
GEP20084378B (en) Composition with hepatoproective and metabolism normalizing activity
AR124100A2 (es) Composiciones farmacéuticas para la administración intratecal de enzimas lisosómicas
AR094481A1 (es) Formulaciones de albu-bche (albúmina-butirilcolinesterasa), preparación y sus usos
AR118157A2 (es) Una enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante, composición y sus usos
RU2021134682A (ru) Доставка терапевтических агентов в цнс

Legal Events

Date Code Title Description
FC Refusal